- Home
- SLRX vs NAOV Comparison
SLRX vs NAOV Comparison
Compare SLRX & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- NAOV
- Stock Information
- Founded
- SLRX N/A
- NAOV 2003
- Country
- SLRX United States
- NAOV United States
- Employees
- SLRX N/A
- NAOV N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- NAOV Industrial Specialties
- Sector
- SLRX Health Care
- NAOV Health Care
- Exchange
- SLRX Nasdaq
- NAOV Nasdaq
- Market Cap
- SLRX 2.1M
- NAOV 2.4M
- IPO Year
- SLRX N/A
- NAOV N/A
- Fundamental
- Price
- SLRX $0.50
- NAOV $0.80
- Analyst Decision
- SLRX
- NAOV
- Analyst Count
- SLRX 0
- NAOV 0
- Target Price
- SLRX N/A
- NAOV N/A
- AVG Volume (30 Days)
- SLRX 6.2M
- NAOV 871.7K
- Earning Date
- SLRX 08-19-2025
- NAOV 08-18-2025
- Dividend Yield
- SLRX N/A
- NAOV N/A
- EPS Growth
- SLRX N/A
- NAOV N/A
- EPS
- SLRX N/A
- NAOV N/A
- Revenue
- SLRX N/A
- NAOV $2,662,000.00
- Revenue This Year
- SLRX N/A
- NAOV N/A
- Revenue Next Year
- SLRX N/A
- NAOV N/A
- P/E Ratio
- SLRX N/A
- NAOV N/A
- Revenue Growth
- SLRX N/A
- NAOV N/A
- 52 Week Low
- SLRX $0.45
- NAOV $0.67
- 52 Week High
- SLRX $7.20
- NAOV $16.25
- Technical
- Relative Strength Index (RSI)
- SLRX 37.62
- NAOV 35.72
- Support Level
- SLRX $0.59
- NAOV $0.80
- Resistance Level
- SLRX $2.31
- NAOV $0.88
- Average True Range (ATR)
- SLRX 0.18
- NAOV 0.07
- MACD
- SLRX -0.02
- NAOV 0.01
- Stochastic Oscillator
- SLRX 2.27
- NAOV 31.61
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.